Interleukin-6/interleukin-10 ratio and immune dysregulation after radiofrequency ablation

Figure 1 Flowchart of patient selection and enrollment with histopathologically confirmed hepatic malignancies undergoing radiofrequency ablation. HCC: Hepatocellular carcinoma; RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization.

Figure 2 Temporal changes in serum interleukin-6 and interleukin-10 levels before and after radiofrequency ablation. A: Serum interleukin (IL)-6 levels significantly increased after radiofrequency ablation (RFA), peaking early post-treatment; B: Serum IL-10 levels showed a moderate increase following RFA; C: IL-6/IL-10 ratio was markedly elevated throughout the post-RFA period. IL: Interleukin.

Figure 3 Receiver operating characteristic curve evaluating the predictive performance of the interleukin-6/interleukin-10 ratio for immune dysregulation following radiofrequency ablation. AUC: Area under the receiver operating characteristic curve.